Time & Date: 2 September, 11:00 – 12:00 CEST
Chairpersons: A. Loewenstein ISRAEL & T. Lai HONG KONG
Speakers & Presentations:
A. Loewenstein ISRAEL
11:00 Welcome
P. Barreto PORTUGAL
11:02 Association of genetics and the adherence to the Mediterranean diet: the risk for age-related macular degeneration
A. Loewenstein ISRAEL
11:08 Efficacy and Safety of a Novel Ranibizumab Biosimilar Versus Reference Ranibizumab (Lucentis®) in Neovascular Age-Related Macular Degeneration
A. Rachitskaya USA
11:14 End-of-Study Retinal Fluid and Vision Outcomes in the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
A. Khanani USA
11:20 Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE® Study
T. Lai HONG KONG
11:32 Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Interval Cohort in the Phase 3 TENAYA and LUCERNE Trials
B. Tombolini ITALY
11:38 OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients
T. Tibaldi ITALY
11:44 A comparison between two automated algorithms to segment the inner and outer retinal thicknesses in eyes with neovascular age-related macular degeneration.
D. Jack Fu JUK
11:50 Automatically segmented qOCT biomarkers are predictive for standard and low luminance visual acuity in geographic atrophy
A. Antropoli ITALY
11:50 Optical Coherence Tomography features in Extensive Macular Atrophy with Pseudodrusen-like appearance versus Geographic Atrophy phenotypes
All Faculty
11:56 Discussion
